World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
49
Citations
10836
World Ranking
4319
National Ranking
1964

Chihiro Morishima publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Chihiro Morishima sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 117 publications — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Chihiro Morishima D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Chihiro Morishima sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 49 D-Index — 13th percentile

13% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Chihiro Morishima is affiliated with the University of Washington in the United States and has contributed extensively to the field of medicine, with a particular focus on infectious diseases. Their research prominently addresses SARS-CoV-2 and COVID-19, covering clinical studies, detection methods, and immune responses.

The scientist's work spans several subfields including infectious diseases, immunology, molecular biology, oncology, and hematology. Morishima's research interests are primarily centered around topics such as SARS-CoV-2 and COVID-19 research, COVID-19 clinical research studies, SARS-CoV-2 detection and testing, immunotherapy and immune responses, CAR-T cell therapy research, cancer immunotherapy and biomarkers, as well as T-cell and B-cell immunology.

Morishima's publications appear frequently in a variety of scientific journals. Notable publication venues include:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • American Journal of Clinical Pathology
  • Journal of Clinical Microbiology
  • JCI Insight
  • The Journal of Immunology

Frequent collaborative partners in Morishima's research include colleagues Mark H. Wener, Susan L. Fink, Andrew Bryan, Anu Chaudhary, and Alexander L. Greninger.

Recent papers authored or co-authored by Morishima feature studies on SARS-CoV-2 detection and immune response, including:

  • Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho (2020, Journal of Clinical Microbiology)
  • Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019 (2020, The Journal of Infectious Diseases)
  • Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients (2020, bioRxiv [Cold Spring Harbor Laboratory])
  • Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets (2020, Nature Cancer)
  • Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19) (2020, Journal of Translational Autoimmunity)

The breadth of Morishima's portfolio indicates a focus on both fundamental immunologic mechanisms and applied clinical research, particularly in the context of emergent viral pathogens and immune therapies related to infectious diseases and oncology.

Best Publications

  • Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease

    Anna S. Lok;Leonard B. Seeff;Timothy R. Morgan;Adrian M. di Bisceglie

  • Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

    Mitchell L. Shiffman;Adrian M. Di Bisceglie;Karen L. Lindsay;Chihiro Morishima

  • Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho.

    Andrew Bryan;Gregory Pepper;Mark H. Wener;Susan L. Fink

  • Outcome of sustained virological responders with histologically advanced chronic hepatitis C

    Timothy R. Morgan;Timothy R. Morgan;Marc G. Ghany;Hae Young Kim;Kristin K. Snow

  • Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

    Adrian M. Di Bisceglie;Mitchell L. Shiffman;Gregory T. Everson;Karen L. Lindsay

  • Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model.

    T A Mustoe;G F Pierce;C Morishima;T F Deuel

  • Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT‐C cohort

    Anna S F Lok;Marc G. Ghany;Zachary D. Goodman;Elizabeth C. Wright

  • Identification of hepatoprotective flavonolignans from silymarin

    Stephen J. Polyak;Chihiro Morishima;Volker Lohmann;Sampa Pal

  • Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.

    Peter D Burbelo;Francis X Riedo;Chihiro Morishima;Stephen Rawlings

  • Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-κB Signaling, and HCV Infection by Standardized Silymarin

    Stephen J. Polyak;Chihiro Morishima;Margaret C. Shuhart;Chia C. Wang

  • Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing.

    Chihiro Morishima;Denise M. Paschal;Chia C. Wang;Christina S. Yoshihara

  • Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C

    Anna S. Lok;James E. Everhart;Elizabeth C. Wright;Adrian M. Di Bisceglie

  • Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C

    Neal D. Freedman;James E. Everhart;Karen L. Lindsay;Marc G. Ghany

  • A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors

    Jeffrey S. Miller;Chihiro Morishima;Douglas G. McNeel;Manish R. Patel

  • Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.

    James E. Everhart;Elizabeth C. Wright;Zachary D. Goodman;Jules L. Dienstag

  • Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.

    Gregory T. Everson;John C. Hoefs;Leonard B. Seeff;Herbert L. Bonkovsky

  • Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.

    Kim Margolin;Chihiro Morishima;Chihiro Morishima;Vamsidhar Velcheti;Jeffrey S. Miller

  • A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C†‡§¶‖

    Jules L. Dienstag;Marc G. Ghany;Timothy R. Morgan;Timothy R. Morgan;Adrian M. Di Bisceglie

  • Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients.

    Peter D Burbelo;Francis X Riedo;Chihiro Morishima;Stephen Rawlings

  • Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: a prospective validation study

    Kelly G. Paulson;Christopher W. Lewis;Mary W. Redman;William T. Simonson

  • Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.

    William M. Lee;Jules L. Dienstag;Karen L. Lindsay;Anna S. Lok

  • Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort Potential conflict of interest: Nothing to report.

    Anna Suk-Fong Lok;Marc G. Ghany;Zachary D. Goodman;Elizabeth C. Wright

Frequent Co-Authors

Herbert L. Bonkovsky
Herbert L. Bonkovsky Wake Forest University
Timothy R. Morgan
Timothy R. Morgan California State University, Long Beach
Adrian M. Di Bisceglie
Adrian M. Di Bisceglie Saint Louis University
Marc G. Ghany
Marc G. Ghany National Institutes of Health
William M. Lee
William M. Lee The University of Texas Southwestern Medical Center
Jules L. Dienstag
Jules L. Dienstag Harvard University
Gregory T. Everson
Gregory T. Everson University of Colorado Denver
James E. Everhart
James E. Everhart National Institutes of Health
Keith R. Jerome
Keith R. Jerome Fred Hutchinson Cancer Research Center
David R. Gretch
David R. Gretch University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Immunology opens doors to diverse healthcare careers, including nursing and specialized practitioner roles. For those interested in entry-level nursing positions, exploring which LPN programs are easiest to get into can provide a strategic starting point. Licensed Practical Nurse programs offer foundational clinical experience and patient care skills essential to healthcare teams.

Advancing further, many immunology graduates consider nurse practitioner roles, particularly in psychiatric and mental health fields. Identifying the easiest nurse practitioner program options can make the path to advanced practice more manageable. This is especially relevant as demand rises for practitioners skilled in immunology-related mental health challenges.

For those specializing in psychiatric care, enrolling in one of the top psychiatric mental health nurse practitioner programs online ensures quality education paired with strong clinical placement opportunities. This combination is crucial for gaining practical experience and excelling in specialty care.

Cost is a vital consideration, and prospective students might benefit from researching the cheapest PMHNP programs to balance quality with affordability. Careful selection of programs can significantly impact both career trajectory and financial investment.

Best Scientists Citing Chihiro Morishima

Trending Scientists

Recently Published Articles